OA12021A - Compounds for the treatment of ischemia. - Google Patents

Compounds for the treatment of ischemia. Download PDF

Info

Publication number: OA12021A
Authority: OA; OAPI
Prior art keywords: alkyl; compound; chloro; pyrazole; mono
Prior art date: 1999-09-30

Application number

OA1200200072A

Other languages

English (en)

Inventor

Michael Paul Deninno

Robert William Scott

Hiroko Masamune

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-30

Filing date

2000-09-22

Publication date

2006-04-19

2000-09-22 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-04-19 Publication of OA12021A publication Critical patent/OA12021A/en

Links

208000028867 ischemia Diseases 0.000 title claims abstract description 26
150000001875 compounds Chemical class 0.000 title claims description 435
238000011282 treatment Methods 0.000 title claims description 20
238000000034 method Methods 0.000 claims abstract description 119
206010021143 Hypoxia Diseases 0.000 claims abstract description 34
230000000451 tissue damage Effects 0.000 claims abstract description 26
231100000827 tissue damage Toxicity 0.000 claims abstract description 26
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
230000007954 hypoxia Effects 0.000 claims abstract description 14
-1 oxy, methylene Chemical group 0.000 claims description 249
125000000217 alkyl group Chemical group 0.000 claims description 189
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 140
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 130
125000003545 alkoxy group Chemical group 0.000 claims description 111
239000000203 mixture Substances 0.000 claims description 95
229920006395 saturated elastomer Polymers 0.000 claims description 88
229910052757 nitrogen Inorganic materials 0.000 claims description 75
229940002612 prodrug Drugs 0.000 claims description 72
239000000651 prodrug Substances 0.000 claims description 72
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 66
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 66
125000005843 halogen group Chemical group 0.000 claims description 60
239000003112 inhibitor Substances 0.000 claims description 55
229910052760 oxygen Inorganic materials 0.000 claims description 55
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 54
239000001301 oxygen Substances 0.000 claims description 54
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims description 50
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 49
229910052717 sulfur Inorganic materials 0.000 claims description 49
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 48
239000011593 sulfur Substances 0.000 claims description 48
210000001519 tissue Anatomy 0.000 claims description 44
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 39
241000124008 Mammalia Species 0.000 claims description 27
125000001309 chloro group Chemical group Cl* 0.000 claims description 27
150000003839 salts Chemical class 0.000 claims description 27
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 26
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
125000004093 cyano group Chemical group *C#N 0.000 claims description 25
125000005842 heteroatom Chemical group 0.000 claims description 25
239000003795 chemical substances by application Substances 0.000 claims description 24
125000003282 alkyl amino group Chemical group 0.000 claims description 23
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 22
125000003386 piperidinyl group Chemical group 0.000 claims description 21
125000002757 morpholinyl group Chemical group 0.000 claims description 20
125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 claims description 19
102000004190 Enzymes Human genes 0.000 claims description 18
108090000790 Enzymes Proteins 0.000 claims description 18
125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims description 18
125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims description 18
229910052799 carbon Inorganic materials 0.000 claims description 17
239000002552 dosage form Substances 0.000 claims description 17
125000002541 furyl group Chemical group 0.000 claims description 17
125000000842 isoxazolyl group Chemical group 0.000 claims description 17
239000003085 diluting agent Substances 0.000 claims description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
125000004193 piperazinyl group Chemical group 0.000 claims description 16
125000000335 thiazolyl group Chemical group 0.000 claims description 16
239000003937 drug carrier Substances 0.000 claims description 15
125000003226 pyrazolyl group Chemical group 0.000 claims description 15
125000000168 pyrrolyl group Chemical group 0.000 claims description 15
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 14
229960005305 adenosine Drugs 0.000 claims description 14
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
125000002619 bicyclic group Chemical group 0.000 claims description 14
125000002971 oxazolyl group Chemical group 0.000 claims description 14
125000004076 pyridyl group Chemical group 0.000 claims description 14
238000001356 surgical procedure Methods 0.000 claims description 14
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 14
239000012190 activator Substances 0.000 claims description 13
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 13
125000006310 cycloalkyl amino group Chemical group 0.000 claims description 13
125000001153 fluoro group Chemical group F* 0.000 claims description 13
230000001603 reducing effect Effects 0.000 claims description 13
239000003981 vehicle Substances 0.000 claims description 13
239000002327 cardiovascular agent Substances 0.000 claims description 12
229940125692 cardiovascular agent Drugs 0.000 claims description 12
125000000000 cycloalkoxy group Chemical group 0.000 claims description 12
125000000753 cycloalkyl group Chemical group 0.000 claims description 12
230000001225 therapeutic effect Effects 0.000 claims description 12
102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 claims description 11
108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 claims description 11
125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
210000004556 brain Anatomy 0.000 claims description 10
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
230000000747 cardiac effect Effects 0.000 claims description 10
125000001786 isothiazolyl group Chemical group 0.000 claims description 10
125000003373 pyrazinyl group Chemical group 0.000 claims description 10
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
210000004185 liver Anatomy 0.000 claims description 9
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 8
125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 8
125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 8
125000004414 alkyl thio group Chemical group 0.000 claims description 8
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 8
125000002393 azetidinyl group Chemical group 0.000 claims description 8
125000001544 thienyl group Chemical group 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
239000011575 calcium Substances 0.000 claims description 6
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 5
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 5
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
239000003379 purinergic P1 receptor agonist Substances 0.000 claims description 5
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
239000005541 ACE inhibitor Substances 0.000 claims description 4
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
229940123208 Biguanide Drugs 0.000 claims description 4
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 4
101100258328 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) crc-2 gene Proteins 0.000 claims description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 claims description 4
102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 claims description 4
108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 claims description 4
101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 claims description 4
229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 4
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
239000005557 antagonist Substances 0.000 claims description 4
125000005605 benzo group Chemical group 0.000 claims description 4
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
239000002876 beta blocker Substances 0.000 claims description 4
229940097320 beta blocking agent Drugs 0.000 claims description 4
150000004283 biguanides Chemical class 0.000 claims description 4
229960002896 clonidine Drugs 0.000 claims description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 4
229960002768 dipyridamole Drugs 0.000 claims description 4
210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
229930182470 glycoside Natural products 0.000 claims description 4
125000001041 indolyl group Chemical group 0.000 claims description 4
210000003734 kidney Anatomy 0.000 claims description 4
229940043355 kinase inhibitor Drugs 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 4
229960003105 metformin Drugs 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
230000003647 oxidation Effects 0.000 claims description 4
238000007254 oxidation reaction Methods 0.000 claims description 4
230000036961 partial effect Effects 0.000 claims description 4
239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 4
229960001289 prazosin Drugs 0.000 claims description 4
210000002027 skeletal muscle Anatomy 0.000 claims description 4
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
125000003831 tetrazolyl group Chemical group 0.000 claims description 4
230000002537 thrombolytic effect Effects 0.000 claims description 4
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 3
108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims description 3
102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims description 3
102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims description 3
108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims description 3
108010018763 Biotin carboxylase Proteins 0.000 claims description 3
102000011727 Caspases Human genes 0.000 claims description 3
108010076667 Caspases Proteins 0.000 claims description 3
101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 3
108090000364 Ligases Proteins 0.000 claims description 3
102000003960 Ligases Human genes 0.000 claims description 3
XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims description 3
102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 3
108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 3
108091026813 Poly(ADPribose) Proteins 0.000 claims description 3
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 3
102000001253 Protein Kinase Human genes 0.000 claims description 3
102000003923 Protein Kinase C Human genes 0.000 claims description 3
108090000315 Protein Kinase C Proteins 0.000 claims description 3
230000002424 anti-apoptotic effect Effects 0.000 claims description 3
108010073240 complement C5a-inhibitors Proteins 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
239000002934 diuretic Substances 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
150000004665 fatty acids Chemical class 0.000 claims description 3
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 3
230000000968 intestinal effect Effects 0.000 claims description 3
239000008024 pharmaceutical diluent Substances 0.000 claims description 3
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
108060006633 protein kinase Proteins 0.000 claims description 3
229960000213 ranolazine Drugs 0.000 claims description 3
210000001032 spinal nerve Anatomy 0.000 claims description 3
210000000952 spleen Anatomy 0.000 claims description 3
WNQKGTWUHOWKHJ-KANGHSEISA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(1,3-thiazol-2-ylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3SC=CN=3)=C2N=C1 WNQKGTWUHOWKHJ-KANGHSEISA-N 0.000 claims description 2
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
102100035023 Carboxypeptidase B2 Human genes 0.000 claims description 2
108090000201 Carboxypeptidase B2 Proteins 0.000 claims description 2
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 2
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
239000000480 calcium channel blocker Substances 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
VGSVDBBUTFVKKP-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-phenylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC=C1 VGSVDBBUTFVKKP-UHFFFAOYSA-N 0.000 claims description 2
125000004043 oxo group Chemical group O=* 0.000 claims description 2
239000002464 receptor antagonist Substances 0.000 claims description 2
229940044551 receptor antagonist Drugs 0.000 claims description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 14
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 6
102000002045 Endothelin Human genes 0.000 claims 4
108050009340 Endothelin Proteins 0.000 claims 4
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 4
229910002651 NO3 Inorganic materials 0.000 claims 3
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 3
150000002338 glycosides Chemical class 0.000 claims 3
239000001103 potassium chloride Substances 0.000 claims 3
235000011164 potassium chloride Nutrition 0.000 claims 3
229960002816 potassium chloride Drugs 0.000 claims 3
102000005862 Angiotensin II Human genes 0.000 claims 2
101800000733 Angiotensin-2 Proteins 0.000 claims 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 2
108010081805 Malonyl-CoA decarboxylase Proteins 0.000 claims 2
102100029461 Malonyl-CoA decarboxylase, mitochondrial Human genes 0.000 claims 2
229950006323 angiotensin ii Drugs 0.000 claims 2
239000003146 anticoagulant agent Substances 0.000 claims 2
230000001882 diuretic effect Effects 0.000 claims 2
229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
239000002777 nucleoside Substances 0.000 claims 2
CHWZXNHFXXEIRA-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-chloro-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3C=CC=CC=3)=C2N=C1 CHWZXNHFXXEIRA-BINBFKAUSA-N 0.000 claims 1
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
BINSRSZWKJTYQD-UHFFFAOYSA-N 1-(2-chloro-5-sulfamoylphenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=C(C=2)S(N)(=O)=O)Cl)C=1C1CC1 BINSRSZWKJTYQD-UHFFFAOYSA-N 0.000 claims 1
AWDVOIVMYCOEGE-UHFFFAOYSA-N 1-(3-chloro-2h-indazol-5-yl)-n-(diaminomethylidene)-5-ethylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(NN=C2Cl)C2=C1 AWDVOIVMYCOEGE-UHFFFAOYSA-N 0.000 claims 1
YZLNQKMWEXOAPY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-phenylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C=CC=CC=2)C=1C1CC1 YZLNQKMWEXOAPY-UHFFFAOYSA-N 0.000 claims 1
108090000312 Calcium Channels Proteins 0.000 claims 1
102000003922 Calcium Channels Human genes 0.000 claims 1
108091006146 Channels Proteins 0.000 claims 1
229940122355 Insulin sensitizer Drugs 0.000 claims 1
125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims 1
WHYRGUVSHCIYOP-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-(3-methylbenzimidazol-5-yl)pyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CN2C)C2=C1 WHYRGUVSHCIYOP-UHFFFAOYSA-N 0.000 claims 1
USEQIAAJQHCEER-UHFFFAOYSA-N n-(diaminomethylidene)-5-methyl-1-[2-(trifluoromethyl)phenyl]pyrazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC=C1C(F)(F)F USEQIAAJQHCEER-UHFFFAOYSA-N 0.000 claims 1
239000004036 potassium channel stimulating agent Substances 0.000 claims 1
210000005166 vasculature Anatomy 0.000 claims 1
239000000556 agonist Substances 0.000 abstract description 10
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 190
238000005160 1H NMR spectroscopy Methods 0.000 description 146
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 120
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 119
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 105
238000005481 NMR spectroscopy Methods 0.000 description 93
238000006243 chemical reaction Methods 0.000 description 91
239000000243 solution Substances 0.000 description 91
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
108010046163 Glycogen Phosphorylase Proteins 0.000 description 66
102000007390 Glycogen Phosphorylase Human genes 0.000 description 66
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
239000002253 acid Substances 0.000 description 50
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 41
125000002887 hydroxy group Chemical group [H]O* 0.000 description 41
230000000694 effects Effects 0.000 description 39
235000019439 ethyl acetate Nutrition 0.000 description 39
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
239000007787 solid Substances 0.000 description 35
150000001412 amines Chemical class 0.000 description 34
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 33
210000004027 cell Anatomy 0.000 description 33
210000002216 heart Anatomy 0.000 description 30
239000002585 base Substances 0.000 description 29
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
229940093499 ethyl acetate Drugs 0.000 description 27
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
238000003818 flash chromatography Methods 0.000 description 26
239000002904 solvent Substances 0.000 description 26
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 24
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
238000003556 assay Methods 0.000 description 21
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 21
239000010410 layer Substances 0.000 description 21
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
239000003921 oil Substances 0.000 description 19
235000019198 oils Nutrition 0.000 description 19
239000012044 organic layer Substances 0.000 description 19
239000003826 tablet Substances 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
230000004224 protection Effects 0.000 description 18
238000012360 testing method Methods 0.000 description 18
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
239000012267 brine Substances 0.000 description 17
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
229960000583 acetic acid Drugs 0.000 description 16
229940088598 enzyme Drugs 0.000 description 16
235000017557 sodium bicarbonate Nutrition 0.000 description 16
229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
239000003288 aldose reductase inhibitor Substances 0.000 description 15
239000000872 buffer Substances 0.000 description 15
230000006378 damage Effects 0.000 description 15
FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 14
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
229910052938 sodium sulfate Inorganic materials 0.000 description 14
235000011152 sodium sulphate Nutrition 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
241000700159 Rattus Species 0.000 description 13
WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 13
201000010099 disease Diseases 0.000 description 13
238000009472 formulation Methods 0.000 description 13
229910052943 magnesium sulfate Inorganic materials 0.000 description 13
235000019341 magnesium sulphate Nutrition 0.000 description 13
208000010125 myocardial infarction Diseases 0.000 description 13
229940118148 Aldose reductase inhibitor Drugs 0.000 description 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
229930091371 Fructose Natural products 0.000 description 12
239000005715 Fructose Substances 0.000 description 12
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 12
230000005961 cardioprotection Effects 0.000 description 12
239000000499 gel Substances 0.000 description 12
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
239000000523 sample Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 11
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
239000002775 capsule Substances 0.000 description 11
239000000463 material Substances 0.000 description 11
230000002107 myocardial effect Effects 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
230000010410 reperfusion Effects 0.000 description 11
239000000600 sorbitol Substances 0.000 description 11
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
239000007832 Na2SO4 Substances 0.000 description 10
150000001540 azides Chemical class 0.000 description 10
238000007675 cardiac surgery Methods 0.000 description 10
239000012442 inert solvent Substances 0.000 description 10
125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 10
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
229920002527 Glycogen Polymers 0.000 description 9
239000007995 HEPES buffer Substances 0.000 description 9
230000004913 activation Effects 0.000 description 9
235000011114 ammonium hydroxide Nutrition 0.000 description 9
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
229940079593 drug Drugs 0.000 description 9
239000003814 drug Substances 0.000 description 9
229940096919 glycogen Drugs 0.000 description 9
BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
206010061216 Infarction Diseases 0.000 description 8
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 8
208000027418 Wounds and injury Diseases 0.000 description 8
HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 8
239000000908 ammonium hydroxide Substances 0.000 description 8
229940043379 ammonium hydroxide Drugs 0.000 description 8
210000004351 coronary vessel Anatomy 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
239000011888 foil Substances 0.000 description 8
230000014509 gene expression Effects 0.000 description 8
229950010772 glucose-1-phosphate Drugs 0.000 description 8
230000007574 infarction Effects 0.000 description 8
208000014674 injury Diseases 0.000 description 8
230000003405 preventing effect Effects 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
235000011054 acetic acid Nutrition 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
239000012230 colorless oil Substances 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
230000001146 hypoxic effect Effects 0.000 description 7
238000011534 incubation Methods 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
229960004592 isopropanol Drugs 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
239000012071 phase Substances 0.000 description 7
125000001424 substituent group Chemical group 0.000 description 7
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 6
102000014750 Phosphorylase Kinase Human genes 0.000 description 6
108010064071 Phosphorylase Kinase Proteins 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
229960004217 benzyl alcohol Drugs 0.000 description 6
238000009739 binding Methods 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
208000029078 coronary artery disease Diseases 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
238000001914 filtration Methods 0.000 description 6
239000012458 free base Substances 0.000 description 6
239000008103 glucose Substances 0.000 description 6
150000004678 hydrides Chemical class 0.000 description 6
125000002883 imidazolyl group Chemical group 0.000 description 6
230000000302 ischemic effect Effects 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
125000002098 pyridazinyl group Chemical group 0.000 description 6
238000010992 reflux Methods 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
239000011734 sodium Substances 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000007858 starting material Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 5
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
101150046889 ADORA3 gene Proteins 0.000 description 5
102100021935 C-C motif chemokine 26 Human genes 0.000 description 5
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 5
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 5
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
102000004316 Oxidoreductases Human genes 0.000 description 5
108090000854 Oxidoreductases Proteins 0.000 description 5
102000009097 Phosphorylases Human genes 0.000 description 5
108010073135 Phosphorylases Proteins 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
229950006790 adenosine phosphate Drugs 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
239000011324 bead Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 5
230000027455 binding Effects 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
230000004087 circulation Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
230000004064 dysfunction Effects 0.000 description 5
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
125000000623 heterocyclic group Chemical group 0.000 description 5
229910052816 inorganic phosphate Inorganic materials 0.000 description 5
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 5
108010052968 leupeptin Proteins 0.000 description 5
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
239000008188 pellet Substances 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
239000002798 polar solvent Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
125000003072 pyrazolidinyl group Chemical group 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
238000012289 standard assay Methods 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
SENYCISNFWIXIL-NCLAMWEWSA-N 2-[2-[[[9-[(2r,3r,4s,5s)-4-azido-3-hydroxy-5-(methylcarbamoyl)oxolan-2-yl]purin-6-yl]amino]methyl]-4-chlorophenoxy]acetic acid Chemical compound O[C@@H]1[C@H](N=[N+]=[N-])[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(O)=O)=C2N=C1 SENYCISNFWIXIL-NCLAMWEWSA-N 0.000 description 4
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
102000055025 Adenosine deaminases Human genes 0.000 description 4
108050000203 Adenosine receptors Proteins 0.000 description 4
102000009346 Adenosine receptors Human genes 0.000 description 4
206010002388 Angina unstable Diseases 0.000 description 4
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
208000007814 Unstable Angina Diseases 0.000 description 4
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
125000000676 alkoxyimino group Chemical group 0.000 description 4
150000001408 amides Chemical group 0.000 description 4
239000000010 aprotic solvent Substances 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
238000000170 chemical ionisation mass spectrum Methods 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
238000001816 cooling Methods 0.000 description 4
238000007887 coronary angioplasty Methods 0.000 description 4
239000007822 coupling agent Substances 0.000 description 4
238000010511 deprotection reaction Methods 0.000 description 4
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000006260 foam Substances 0.000 description 4
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 4
210000005003 heart tissue Anatomy 0.000 description 4
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000005462 in vivo assay Methods 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000001802 infusion Methods 0.000 description 4
201000004332 intermediate coronary syndrome Diseases 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
210000005240 left ventricle Anatomy 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
210000004165 myocardium Anatomy 0.000 description 4
239000002245 particle Substances 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
229910000073 phosphorus hydride Inorganic materials 0.000 description 4
239000003880 polar aprotic solvent Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 4
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
238000010791 quenching Methods 0.000 description 4
238000011084 recovery Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
239000012279 sodium borohydride Substances 0.000 description 4
229910000033 sodium borohydride Inorganic materials 0.000 description 4
239000000829 suppository Substances 0.000 description 4
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
238000007631 vascular surgery Methods 0.000 description 4
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
RIIVBOIBIOLLPO-UHFFFAOYSA-N 2-phthalazin-1-ylacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NN=CC2=C1 RIIVBOIBIOLLPO-UHFFFAOYSA-N 0.000 description 3
ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
206010007572 Cardiac hypertrophy Diseases 0.000 description 3
208000006029 Cardiomegaly Diseases 0.000 description 3
101710088194 Dehydrogenase Proteins 0.000 description 3
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
101000702479 Homo sapiens Sodium/hydrogen exchanger 1 Proteins 0.000 description 3
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 3
239000007836 KH2PO4 Substances 0.000 description 3
108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 3
102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
206010067125 Liver injury Diseases 0.000 description 3
229940122294 Phosphorylase inhibitor Drugs 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
102100022897 Sodium/hydrogen exchanger 10 Human genes 0.000 description 3
102100026974 Sorbitol dehydrogenase Human genes 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
150000003838 adenosines Chemical class 0.000 description 3
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
206010003119 arrhythmia Diseases 0.000 description 3
230000006793 arrhythmia Effects 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
235000014121 butter Nutrition 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000010367 cloning Methods 0.000 description 3
229910052681 coesite Inorganic materials 0.000 description 3
238000006482 condensation reaction Methods 0.000 description 3
229910052906 cristobalite Inorganic materials 0.000 description 3
238000011161 development Methods 0.000 description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000007429 general method Methods 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000005858 glycosidation reaction Methods 0.000 description 3
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
229960003132 halothane Drugs 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
231100000234 hepatic damage Toxicity 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
238000010255 intramuscular injection Methods 0.000 description 3
239000007927 intramuscular injection Substances 0.000 description 3
229940039009 isoproterenol Drugs 0.000 description 3
230000008818 liver damage Effects 0.000 description 3
238000011068 loading method Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
235000019796 monopotassium phosphate Nutrition 0.000 description 3
208000031225 myocardial ischemia Diseases 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
229960001412 pentobarbital Drugs 0.000 description 3
108010091212 pepstatin Proteins 0.000 description 3
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
230000001292 preischemic effect Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
125000002755 pyrazolinyl group Chemical group 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
210000001525 retina Anatomy 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
229910052682 stishovite Inorganic materials 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
229910052905 tridymite Inorganic materials 0.000 description 3
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
XATPVVFBAPJNKA-FULWYAMNSA-N (2S,3S,4R,5R)-3-azido-5-(6-chloropurin-9-yl)-4-hydroxyoxolane-2-carboxylic acid Chemical compound O[C@H]1[C@@H](O[C@@H]([C@H]1N=[N+]=[N-])C(O)=O)n1cnc2c(Cl)ncnc12 XATPVVFBAPJNKA-FULWYAMNSA-N 0.000 description 2
POBVXBAPVRDWBC-SFSWPSDLSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(oxolan-3-ylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC3COCC3)=C2N=C1 POBVXBAPVRDWBC-SFSWPSDLSA-N 0.000 description 2
125000006529 (C3-C6) alkyl group Chemical group 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 description 2
YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 2
PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
RFPGCNBLGKQHSQ-UHFFFAOYSA-N 2-(azidomethyl)-1-phenylmethoxy-4-(trifluoromethyl)benzene Chemical compound [N-]=[N+]=NCC1=CC(C(F)(F)F)=CC=C1OCC1=CC=CC=C1 RFPGCNBLGKQHSQ-UHFFFAOYSA-N 0.000 description 2
NIOLZAAXTAPCIV-UHFFFAOYSA-N 2-(azidomethyl)-4-ethynyl-1-phenylmethoxybenzene Chemical compound [N-]=[N+]=NCC1=CC(C#C)=CC=C1OCC1=CC=CC=C1 NIOLZAAXTAPCIV-UHFFFAOYSA-N 0.000 description 2
BPQLVVVBDFGOST-UHFFFAOYSA-N 2-[2-(aminomethyl)-4-chlorophenoxy]acetonitrile Chemical compound NCC1=CC(Cl)=CC=C1OCC#N BPQLVVVBDFGOST-UHFFFAOYSA-N 0.000 description 2
LKBFFDOJUKLQNY-UHFFFAOYSA-N 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Br)C=C1F LKBFFDOJUKLQNY-UHFFFAOYSA-N 0.000 description 2
YSFMIVOTLGOPNO-UHFFFAOYSA-N 2-[[5-chloro-2-(1,2-thiazol-5-ylmethoxy)phenyl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC(Cl)=CC=C1OCC1=CC=NS1 YSFMIVOTLGOPNO-UHFFFAOYSA-N 0.000 description 2
QGYOZMIGOMSRQE-UHFFFAOYSA-N 2-[[5-chloro-2-[(3-methyl-1,2-oxazol-5-yl)methoxy]phenyl]methyl]isoindole-1,3-dione Chemical compound O1N=C(C)C=C1COC1=CC=C(Cl)C=C1CN1C(=O)C2=CC=CC=C2C1=O QGYOZMIGOMSRQE-UHFFFAOYSA-N 0.000 description 2
BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical group O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 2
VIMFODQAJMSULN-UHFFFAOYSA-N 3-(2-morpholin-4-ylethoxy)benzaldehyde Chemical compound O=CC1=CC=CC(OCCN2CCOCC2)=C1 VIMFODQAJMSULN-UHFFFAOYSA-N 0.000 description 2
CQLOSIFKNLRUBF-UHFFFAOYSA-N 3-(azidomethyl)-4-phenylmethoxybenzonitrile Chemical compound [N-]=[N+]=NCC1=CC(C#N)=CC=C1OCC1=CC=CC=C1 CQLOSIFKNLRUBF-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
LXYOEDGDQBDZFK-UHFFFAOYSA-N 5-bromo-2-phenylmethoxybenzaldehyde Chemical compound O=CC1=CC(Br)=CC=C1OCC1=CC=CC=C1 LXYOEDGDQBDZFK-UHFFFAOYSA-N 0.000 description 2
QAHXODZQZVDSGX-UHFFFAOYSA-N 5-chloro-2-(oxolan-3-ylmethoxy)benzonitrile Chemical compound N#CC1=CC(Cl)=CC=C1OCC1COCC1 QAHXODZQZVDSGX-UHFFFAOYSA-N 0.000 description 2
PTVBGVLITQPZTD-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2,6-dichlorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2Cl)Cl)C=1C1CC1 PTVBGVLITQPZTD-UHFFFAOYSA-N 0.000 description 2
VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical group [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
102000016912 Aldehyde Reductase Human genes 0.000 description 2
108010053754 Aldehyde reductase Proteins 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
PWQJASDYRGVGAC-BTPAMZMASA-N C1COCC1COC2=C(C=C(C=C2)Cl)CNC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(=O)O)N=[N+]=[N-])O Chemical compound C1COCC1COC2=C(C=C(C=C2)Cl)CNC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(=O)O)N=[N+]=[N-])O PWQJASDYRGVGAC-BTPAMZMASA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
239000002593 adenosine A3 receptor agonist Substances 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
230000001668 ameliorated effect Effects 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
101150099875 atpE gene Proteins 0.000 description 2
101150018639 atpFH gene Proteins 0.000 description 2
101150048329 atpH gene Proteins 0.000 description 2
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
229960004365 benzoic acid Drugs 0.000 description 2
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
VPAQNEWOEWGJLF-UHFFFAOYSA-N benzyl 2-phenylmethoxy-5-(2-trimethylsilylethynyl)benzoate Chemical compound C=1C=CC=CC=1COC(=O)C1=CC(C#C[Si](C)(C)C)=CC=C1OCC1=CC=CC=C1 VPAQNEWOEWGJLF-UHFFFAOYSA-N 0.000 description 2
TWTKQHFYKNGJGF-UHFFFAOYSA-N benzyl 5-ethynyl-2-phenylmethoxybenzoate Chemical compound C=1C(C#C)=CC=C(OCC=2C=CC=CC=2)C=1C(=O)OCC1=CC=CC=C1 TWTKQHFYKNGJGF-UHFFFAOYSA-N 0.000 description 2
BPPMHCSGRHHXSV-UHFFFAOYSA-N benzyl 5-fluoro-2-phenylmethoxybenzoate Chemical compound C=1C=CC=CC=1COC(=O)C1=CC(F)=CC=C1OCC1=CC=CC=C1 BPPMHCSGRHHXSV-UHFFFAOYSA-N 0.000 description 2
YQMOCEIRTABVFT-UHFFFAOYSA-N benzyl 5-iodo-2-phenylmethoxybenzoate Chemical compound C=1C=CC=CC=1COC(=O)C1=CC(I)=CC=C1OCC1=CC=CC=C1 YQMOCEIRTABVFT-UHFFFAOYSA-N 0.000 description 2
239000007844 bleaching agent Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
230000006931 brain damage Effects 0.000 description 2
231100000874 brain damage Toxicity 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
244000309466 calf Species 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
238000004821 distillation Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
230000005284 excitation Effects 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
239000007789 gas Substances 0.000 description 2
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
230000004116 glycogenolysis Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
230000012105 intracellular pH reduction Effects 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
DHWHVXWZHNDIDB-UHFFFAOYSA-N methyl 4-methylthiadiazole-5-carboxylate Chemical compound COC(=O)C=1SN=NC=1C DHWHVXWZHNDIDB-UHFFFAOYSA-N 0.000 description 2
GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
208000002089 myocardial stunning Diseases 0.000 description 2
229950006238 nadide Drugs 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
239000004033 plastic Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
235000008160 pyridoxine Nutrition 0.000 description 2
239000011677 pyridoxine Substances 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
238000000527 sonication Methods 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
238000005556 structure-activity relationship Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
YMQZYTYWWIODAL-UHFFFAOYSA-N tert-butyl 2-(4-chloro-2-cyanophenoxy)acetate Chemical compound CC(C)(C)OC(=O)COC1=CC=C(Cl)C=C1C#N YMQZYTYWWIODAL-UHFFFAOYSA-N 0.000 description 2
MNHMBOMZUYIUHR-UHFFFAOYSA-N tert-butyl 2-[2-(aminomethyl)-4-chlorophenoxy]acetate Chemical compound CC(C)(C)OC(=O)COC1=CC=C(Cl)C=C1CN MNHMBOMZUYIUHR-UHFFFAOYSA-N 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
230000009092 tissue dysfunction Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000012137 tryptone Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
229940011671 vitamin b6 Drugs 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
229950005346 zopolrestat Drugs 0.000 description 2
BFCDFTHTSVTWOG-PXNSSMCTSA-N (1r,2s)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol Chemical compound CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-PXNSSMCTSA-N 0.000 description 1
PRYCPQVARRDRFD-LBPRGKRZSA-N (2S)-2-amino-1-(3-hydroxyiminopyrrolidin-1-yl)-3-phenylpropan-1-one Chemical compound C1CN(CC1=NO)C(=O)[C@H](CC2=CC=CC=C2)N PRYCPQVARRDRFD-LBPRGKRZSA-N 0.000 description 1
KGEUMEIBPJTOOI-GBEXAXCTSA-N (2S,3R,4S,5R)-5-(hydroxymethyl)-2-trityloxolane-2,3,4-triol Chemical compound C1(=CC=CC=C1)C(C1=CC=CC=C1)(C1=CC=CC=C1)[C@@]1(O)[C@H](O)[C@H](O)[C@H](O1)CO KGEUMEIBPJTOOI-GBEXAXCTSA-N 0.000 description 1
SZIHJKIVFFMSDJ-XIXAVDCQSA-N (2S,3S,4R,5R)-3-amino-5-[6-[[5-chloro-2-[2-oxo-2-(4-propan-2-ylpiperazin-1-yl)ethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxyoxolane-2-carboxylic acid Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C(C)C)C(=O)O SZIHJKIVFFMSDJ-XIXAVDCQSA-N 0.000 description 1
OYFUGEGRXVCRMU-IZCITBFLSA-N (2S,3S,4R,5R)-4-acetyloxy-3-azido-5-(6-chloropurin-9-yl)oxolane-2-carboxylic acid Chemical compound CC(=O)O[C@H]1[C@@H](O[C@@H]([C@H]1N=[N+]=[N-])C(O)=O)n1cnc2c(Cl)ncnc12 OYFUGEGRXVCRMU-IZCITBFLSA-N 0.000 description 1
NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 description 1
MRPKNNSABYPGBF-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-(benzylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC=CC=3)=C2N=C1 MRPKNNSABYPGBF-LSCFUAHRSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
OHDLXXYYMRWHDG-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-bromo-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Br)C=3)OCC=3C=CC=CC=3)=C2N=C1 OHDLXXYYMRWHDG-BINBFKAUSA-N 0.000 description 1
RSRYKWOKIWAOEH-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-cyano-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)=C2N=C1 RSRYKWOKIWAOEH-GGISIDAXSA-N 0.000 description 1
MPMDWHDDYYIXQU-ONLLFZDPSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-ethynyl-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(C=3)C#C)OCC=3C=CC=CC=3)=C2N=C1 MPMDWHDDYYIXQU-ONLLFZDPSA-N 0.000 description 1
JAKKCOVQWXMHGR-BINBFKAUSA-N (2s,3s,4r,5r)-3-amino-5-[6-[(5-fluoro-2-phenylmethoxyphenyl)methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(F)C=3)OCC=3C=CC=CC=3)=C2N=C1 JAKKCOVQWXMHGR-BINBFKAUSA-N 0.000 description 1
NVOQTJOPEVSGOF-QYUDBREXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-(furan-3-ylmethoxy)phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC3=COC=C3)=C2N=C1 NVOQTJOPEVSGOF-QYUDBREXSA-N 0.000 description 1
ROYWRTZDLNCDMY-CKNWLIOYSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(3,4,5,6-tetrahydroxyoxan-2-yl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC3C(C(O)C(O)C(O)O3)O)=C2N=C1 ROYWRTZDLNCDMY-CKNWLIOYSA-N 0.000 description 1
PKUZHLZHLVHAIO-QYUDBREXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[(3-methyl-1,2-oxazol-5-yl)methoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC=3ON=C(C)C=3)=C2N=C1 PKUZHLZHLVHAIO-QYUDBREXSA-N 0.000 description 1
VCNDJDRVUGHRDV-GGISIDAXSA-N (2s,3s,4r,5r)-3-amino-5-[6-[[5-chloro-2-[2-(dipropylamino)-2-oxoethoxy]phenyl]methylamino]purin-9-yl]-4-hydroxy-n-methyloxolane-2-carboxamide Chemical compound CCCN(CCC)C(=O)COC1=CC=C(Cl)C=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](N)[C@@H](C(=O)NC)O1 VCNDJDRVUGHRDV-GGISIDAXSA-N 0.000 description 1
NDYMQOUYJJXCKJ-UHFFFAOYSA-N (4-fluorophenyl)-morpholin-4-ylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CCOCC1 NDYMQOUYJJXCKJ-UHFFFAOYSA-N 0.000 description 1
SRJRJOYFPZRDNH-NSHDSACASA-N (4s)-6-fluorospiro[3h-chromene-4,5'-imidazolidine]-2,4'-dione Chemical compound C12=CC(F)=CC=C2OC(=O)C[C@@]21NCNC2=O SRJRJOYFPZRDNH-NSHDSACASA-N 0.000 description 1
FRLAPJUTCPQDCQ-UHFFFAOYSA-N (5-bromo-2-phenylmethoxyphenyl)methanamine Chemical compound NCC1=CC(Br)=CC=C1OCC1=CC=CC=C1 FRLAPJUTCPQDCQ-UHFFFAOYSA-N 0.000 description 1
AIDBRISXEJMHLS-UHFFFAOYSA-N (5-bromo-2-phenylmethoxyphenyl)methanol Chemical compound OCC1=CC(Br)=CC=C1OCC1=CC=CC=C1 AIDBRISXEJMHLS-UHFFFAOYSA-N 0.000 description 1
GIGGUFCYUVFLJZ-UHFFFAOYSA-N (5-chloro-2-methoxyphenyl)methanamine Chemical compound COC1=CC=C(Cl)C=C1CN GIGGUFCYUVFLJZ-UHFFFAOYSA-N 0.000 description 1
QYSMZKNNHZHMAM-UHFFFAOYSA-N (5-chloro-2-phenylmethoxyphenyl)methanamine;hydrochloride Chemical compound Cl.NCC1=CC(Cl)=CC=C1OCC1=CC=CC=C1 QYSMZKNNHZHMAM-UHFFFAOYSA-N 0.000 description 1
OTKNUEDHMVFWGR-UHFFFAOYSA-N (5-ethenyl-2-phenylmethoxyphenyl)methanamine Chemical compound NCC1=CC(C=C)=CC=C1OCC1=CC=CC=C1 OTKNUEDHMVFWGR-UHFFFAOYSA-N 0.000 description 1
OKEKWKKCULFXBU-UHFFFAOYSA-N (5-ethynyl-2-phenylmethoxyphenyl)methanamine Chemical compound NCC1=CC(C#C)=CC=C1OCC1=CC=CC=C1 OKEKWKKCULFXBU-UHFFFAOYSA-N 0.000 description 1
NDOHRIIEQFBCLX-UHFFFAOYSA-N (5-fluoro-2-phenylmethoxyphenyl)methanamine Chemical compound NCC1=CC(F)=CC=C1OCC1=CC=CC=C1 NDOHRIIEQFBCLX-UHFFFAOYSA-N 0.000 description 1
RAYWDRUTHRDDBP-UHFFFAOYSA-N (5-iodo-2-phenylmethoxyphenyl)methanamine Chemical compound NCC1=CC(I)=CC=C1OCC1=CC=CC=C1 RAYWDRUTHRDDBP-UHFFFAOYSA-N 0.000 description 1
125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 1
125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 description 1
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
ZJQFENWMXOATQM-UHFFFAOYSA-N 1-(2-chloro-4-methylsulfonylphenyl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1N1C(C2CC2)=C(C(=O)NC(N)=N)C=N1 ZJQFENWMXOATQM-UHFFFAOYSA-N 0.000 description 1
NHFITSUMYNECAK-UHFFFAOYSA-N 1-(3h-benzimidazol-5-yl)-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C=C3NC=NC3=CC=2)C=1C1CC1 NHFITSUMYNECAK-UHFFFAOYSA-N 0.000 description 1
UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
IUNWBIVVJWUTEI-DOWOIAEBSA-N 1-[2-[2-[[[9-[(2r,3r,4s,5s)-4-azido-3-hydroxy-5-(methylcarbamoyl)oxolan-2-yl]purin-6-yl]amino]methyl]-4-chlorophenoxy]acetyl]piperidine-4-carboxamide Chemical compound O[C@@H]1[C@H](N=[N+]=[N-])[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(=O)N3CCC(CC3)C(N)=O)=C2N=C1 IUNWBIVVJWUTEI-DOWOIAEBSA-N 0.000 description 1
HQMDTNPGJUCYMV-UHFFFAOYSA-N 1-[2-chloro-4-(methylsulfamoyl)phenyl]-5-cyclopropyl-n-(diaminomethylidene)pyrazole-4-carboxamide Chemical compound ClC1=CC(S(=O)(=O)NC)=CC=C1N1C(C2CC2)=C(C(=O)NC(N)=N)C=N1 HQMDTNPGJUCYMV-UHFFFAOYSA-N 0.000 description 1
125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
QTQJJXDHMKCEIE-UHFFFAOYSA-N 2-(azidomethyl)-4-bromo-1-phenylmethoxybenzene Chemical compound [N-]=[N+]=NCC1=CC(Br)=CC=C1OCC1=CC=CC=C1 QTQJJXDHMKCEIE-UHFFFAOYSA-N 0.000 description 1
VJOXULMSAGMSAX-UHFFFAOYSA-N 2-(azidomethyl)-4-ethenyl-1-phenylmethoxybenzene Chemical compound [N-]=[N+]=NCC1=CC(C=C)=CC=C1OCC1=CC=CC=C1 VJOXULMSAGMSAX-UHFFFAOYSA-N 0.000 description 1
DLUNPDOFKZGAOR-UHFFFAOYSA-N 2-(azidomethyl)-4-fluoro-1-phenylmethoxybenzene Chemical compound [N-]=[N+]=NCC1=CC(F)=CC=C1OCC1=CC=CC=C1 DLUNPDOFKZGAOR-UHFFFAOYSA-N 0.000 description 1
SKZVOAWTTJEXDD-UHFFFAOYSA-N 2-(azidomethyl)-4-iodo-1-phenylmethoxybenzene Chemical compound [N-]=[N+]=NCC1=CC(I)=CC=C1OCC1=CC=CC=C1 SKZVOAWTTJEXDD-UHFFFAOYSA-N 0.000 description 1
TYIVKRWMOBHQQZ-UHFFFAOYSA-N 2-(azidomethyl)-4-methyl-1-phenylmethoxybenzene Chemical compound [N-]=[N+]=NCC1=CC(C)=CC=C1OCC1=CC=CC=C1 TYIVKRWMOBHQQZ-UHFFFAOYSA-N 0.000 description 1
BZNXQEYFQIMNTN-UHFFFAOYSA-N 2-(hydroxymethyl)-4-(trifluoromethyl)phenol Chemical compound OCC1=CC(C(F)(F)F)=CC=C1O BZNXQEYFQIMNTN-UHFFFAOYSA-N 0.000 description 1
VYDWYBNRDMDXCU-UHFFFAOYSA-N 2-[(5-chloro-2-hydroxyphenyl)methyl]isoindole-1,3-dione Chemical compound OC1=CC=C(Cl)C=C1CN1C(=O)C2=CC=CC=C2C1=O VYDWYBNRDMDXCU-UHFFFAOYSA-N 0.000 description 1
FNVOGEFQORUYDU-UHFFFAOYSA-N 2-[2-(azidomethyl)-4-chlorophenoxy]acetonitrile Chemical compound ClC1=CC=C(OCC#N)C(CN=[N+]=[N-])=C1 FNVOGEFQORUYDU-UHFFFAOYSA-N 0.000 description 1
QTAUUWSYRMVXFM-NCLAMWEWSA-N 2-[2-[[[9-[(2r,3r,4s,5s)-4-amino-3-hydroxy-5-(methylcarbamoyl)oxolan-2-yl]purin-6-yl]amino]methyl]-4-chlorophenoxy]acetic acid Chemical compound O[C@@H]1[C@H](N)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=C(Cl)C=3)OCC(O)=O)=C2N=C1 QTAUUWSYRMVXFM-NCLAMWEWSA-N 0.000 description 1
XSHTXZXPLDNDKC-UHFFFAOYSA-N 2-[3-[(5,7-dichloro-1,3-benzothiazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(Cl)=CC(Cl)=C2S1 XSHTXZXPLDNDKC-UHFFFAOYSA-N 0.000 description 1
KNWXUWPPDTZSFW-UHFFFAOYSA-N 2-[3-[(5,7-difluoro-1,3-benzothiazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC(F)=C2S1 KNWXUWPPDTZSFW-UHFFFAOYSA-N 0.000 description 1
GDULRSFIHLMHJW-UHFFFAOYSA-N 2-[3-[(5,7-difluoro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC(F)=C2O1 GDULRSFIHLMHJW-UHFFFAOYSA-N 0.000 description 1
LURVWPRCGVAWKT-UHFFFAOYSA-N 2-[3-[(5-chloro-1,3-benzoxazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(Cl)=CC=C2O1 LURVWPRCGVAWKT-UHFFFAOYSA-N 0.000 description 1
QUBABKJOUGUHAK-UHFFFAOYSA-N 2-[3-[(5-fluoro-1,3-benzothiazol-2-yl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(F)=CC=C2S1 QUBABKJOUGUHAK-UHFFFAOYSA-N 0.000 description 1
BUYWFAJWTSIACV-UHFFFAOYSA-N 2-[3-oxo-4-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]-1,4-benzothiazin-2-yl]acetic acid Chemical compound FC1=CC(F)=C2SC(CN3C4=CC=CC=C4SC(C3=O)CC(=O)O)=NC2=C1F BUYWFAJWTSIACV-UHFFFAOYSA-N 0.000 description 1
QKRGDZKQCDTVMW-UHFFFAOYSA-N 2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzoxazol-2-yl]methyl]phthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2O1 QKRGDZKQCDTVMW-UHFFFAOYSA-N 0.000 description 1
XXTANQMJCXDKSQ-UHFFFAOYSA-N 2-[[2-(1-benzofuran-2-ylmethoxy)-5-chlorophenyl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC(Cl)=CC=C1OCC1=CC2=CC=CC=C2O1 XXTANQMJCXDKSQ-UHFFFAOYSA-N 0.000 description 1
OOYACBWFUIUHFV-UHFFFAOYSA-N 2-[[5-chloro-2-(pyridin-3-ylmethoxy)phenyl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC(Cl)=CC=C1OCC1=CC=CN=C1 OOYACBWFUIUHFV-UHFFFAOYSA-N 0.000 description 1
ROKXKTSTLJJJFT-UHFFFAOYSA-N 2-[[5-chloro-2-(quinolin-2-ylmethoxy)phenyl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC(Cl)=CC=C1OCC1=CC=C(C=CC=C2)C2=N1 ROKXKTSTLJJJFT-UHFFFAOYSA-N 0.000 description 1
AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
TWKHGKCRNDRGFY-UHFFFAOYSA-N 2-amino-1-(1,1-dioxo-1,3-thiazolidin-3-yl)ethanone Chemical compound NCC(=O)N1CCS(=O)(=O)C1 TWKHGKCRNDRGFY-UHFFFAOYSA-N 0.000 description 1
AVGBKIPAXGXJQH-SYDPRGILSA-N 2-amino-1-[(3S,4R)-3,4-dihydroxypyrrolidin-1-yl]ethanone Chemical compound NCC(=O)N1C[C@H](O)[C@H](O)C1 AVGBKIPAXGXJQH-SYDPRGILSA-N 0.000 description 1
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
YCOCXLVVCILWSG-UHFFFAOYSA-N 2-hydroxyoxolane-2-carboxylic acid Chemical compound OC(=O)C1(O)CCCO1 YCOCXLVVCILWSG-UHFFFAOYSA-N 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
YDAQQRLZYMYLDB-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrochloride Chemical compound Cl.OC1=CC=CC2=C1N=NN2 YDAQQRLZYMYLDB-UHFFFAOYSA-N 0.000 description 1
125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
YZXQTQCTOMWSSU-UHFFFAOYSA-N 3-(aminomethyl)-4-phenylmethoxybenzonitrile Chemical compound NCC1=CC(C#N)=CC=C1OCC1=CC=CC=C1 YZXQTQCTOMWSSU-UHFFFAOYSA-N 0.000 description 1
UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
238000013030 3-step procedure Methods 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
PITVZRMNFBGRFW-UHFFFAOYSA-N 5,6-dichloro-1h-indole-2-carboxylic acid Chemical compound ClC1=C(Cl)C=C2NC(C(=O)O)=CC2=C1 PITVZRMNFBGRFW-UHFFFAOYSA-N 0.000 description 1
MKKSTJKBKNCMRV-UHFFFAOYSA-N 5-bromo-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Br)C=C1C=O MKKSTJKBKNCMRV-UHFFFAOYSA-N 0.000 description 1
NGHMKLRBKIPQRY-UHFFFAOYSA-N 5-butyl-n-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide Chemical compound CCCCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=CC2=NC=CC=C12 NGHMKLRBKIPQRY-UHFFFAOYSA-N 0.000 description 1
CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
WDBGZHPAQXDCJQ-UHFFFAOYSA-N 5-chloro-2-(cyclobutylmethoxy)benzonitrile Chemical compound N#CC1=CC(Cl)=CC=C1OCC1CCC1 WDBGZHPAQXDCJQ-UHFFFAOYSA-N 0.000 description 1
QHGDDYKTVGZHNR-UHFFFAOYSA-N 5-chloro-2-(furan-2-ylmethoxy)benzonitrile Chemical compound N#CC1=CC(Cl)=CC=C1OCC1=CC=CO1 QHGDDYKTVGZHNR-UHFFFAOYSA-N 0.000 description 1
MBEVJBRPXNPLFZ-UHFFFAOYSA-N 5-chloro-2-[(2,5-dimethylfuran-3-yl)methoxy]benzonitrile Chemical compound O1C(C)=CC(COC=2C(=CC(Cl)=CC=2)C#N)=C1C MBEVJBRPXNPLFZ-UHFFFAOYSA-N 0.000 description 1
MROWTGJSNHNFMR-UHFFFAOYSA-N 5-chloro-2-[(2-methoxyphenyl)methoxy]benzonitrile Chemical compound COC1=CC=CC=C1COC1=CC=C(Cl)C=C1C#N MROWTGJSNHNFMR-UHFFFAOYSA-N 0.000 description 1
NZQOIRXQDMFPIX-UHFFFAOYSA-N 5-chloro-2-[(2-methylphenyl)methoxy]benzonitrile Chemical compound CC1=CC=CC=C1COC1=CC=C(Cl)C=C1C#N NZQOIRXQDMFPIX-UHFFFAOYSA-N 0.000 description 1
BMNZGAYSLXLQKY-UHFFFAOYSA-N 5-chloro-2-[(3-methoxyphenyl)methoxy]benzonitrile Chemical compound COC1=CC=CC(COC=2C(=CC(Cl)=CC=2)C#N)=C1 BMNZGAYSLXLQKY-UHFFFAOYSA-N 0.000 description 1
YMIZMOAOVBQEJK-UHFFFAOYSA-N 5-chloro-2-[(3-methylphenyl)methoxy]benzonitrile Chemical compound CC1=CC=CC(COC=2C(=CC(Cl)=CC=2)C#N)=C1 YMIZMOAOVBQEJK-UHFFFAOYSA-N 0.000 description 1
HVFRGZDMJTZSEF-UHFFFAOYSA-N 5-chloro-2-[(4-methoxyphenyl)methoxy]benzonitrile Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(Cl)C=C1C#N HVFRGZDMJTZSEF-UHFFFAOYSA-N 0.000 description 1
FXHVCRLGOLAGLY-UHFFFAOYSA-N 5-chloro-2-[(4-methylphenyl)methoxy]benzonitrile Chemical compound C1=CC(C)=CC=C1COC1=CC=C(Cl)C=C1C#N FXHVCRLGOLAGLY-UHFFFAOYSA-N 0.000 description 1
DJLDDKSLUXGBRN-UHFFFAOYSA-N 5-chloro-2-[[5-[(dimethylamino)methyl]furan-2-yl]methoxy]benzonitrile Chemical compound O1C(CN(C)C)=CC=C1COC1=CC=C(Cl)C=C1C#N DJLDDKSLUXGBRN-UHFFFAOYSA-N 0.000 description 1
KLLOIWZUJAJGPU-IBGZPJMESA-N 5-chloro-n-[(2s)-1-(3-hydroxyazetidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-1h-indole-2-carboxamide Chemical compound C1C(O)CN1C(=O)[C@@H](NC(=O)C=1NC2=CC=C(Cl)C=C2C=1)CC1=CC=CC=C1 KLLOIWZUJAJGPU-IBGZPJMESA-N 0.000 description 1
XCLXHRBTKOPLRH-IBGZPJMESA-N 5-chloro-n-[(2s)-1-(3-hydroxyiminoazetidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-1h-indole-2-carboxamide Chemical compound C1C(=NO)CN1C(=O)[C@@H](NC(=O)C=1NC2=CC=C(Cl)C=C2C=1)CC1=CC=CC=C1 XCLXHRBTKOPLRH-IBGZPJMESA-N 0.000 description 1
FTMFRKISBMECSW-SLFFLAALSA-N 5-chloro-n-[(2s)-1-[(3r,4s)-3,4-dihydroxypyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-1h-indole-2-carboxamide Chemical compound C1[C@@H](O)[C@@H](O)CN1C(=O)[C@@H](NC(=O)C=1NC2=CC=C(Cl)C=C2C=1)CC1=CC=CC=C1 FTMFRKISBMECSW-SLFFLAALSA-N 0.000 description 1
LGOPZILIFLMNPA-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-(2,3-dichlorophenyl)pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=C(Cl)C=CC=2)Cl)C=1C1CC1 LGOPZILIFLMNPA-UHFFFAOYSA-N 0.000 description 1
LFXTUZDNFLZCNR-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-[2-(trifluoromethyl)phenyl]pyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C(=CC=CC=2)C(F)(F)F)C=1C1CC1 LFXTUZDNFLZCNR-UHFFFAOYSA-N 0.000 description 1
NQDZNLKMTLAUGA-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-4-ylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C3=CC=CC=C3N=CC=2)C=1C1CC1 NQDZNLKMTLAUGA-UHFFFAOYSA-N 0.000 description 1
GDXBRVCQGGKXJY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide Chemical compound NC(N)=NC(=O)C=1C=NN(C=2C3=CC=CN=C3C=CC=2)C=1C1CC1 GDXBRVCQGGKXJY-UHFFFAOYSA-N 0.000 description 1
LFOAPSAWYUILCY-UHFFFAOYSA-N 5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-8-ylpyrazole-4-carboxamide Chemical compound NC(=N)NC(=O)C=1C=NN(C=2C3=NC=CC=C3C=CC=2)C=1C1CC1 LFOAPSAWYUILCY-UHFFFAOYSA-N 0.000 description 1
JWPRICQKUNODPZ-UHFFFAOYSA-N 5-fluoro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1O JWPRICQKUNODPZ-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
101150007969 ADORA1 gene Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
229940122216 Adenosine A3 receptor agonist Drugs 0.000 description 1
229940122614 Adenosine receptor agonist Drugs 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
KIVROEXINHPJSH-ZDUSSCGKSA-N C([C@H](N)C(=O)N1CCC(CC1)=NO)C1=CC=CC=C1 Chemical compound C([C@H](N)C(=O)N1CCC(CC1)=NO)C1=CC=CC=C1 KIVROEXINHPJSH-ZDUSSCGKSA-N 0.000 description 1
SHJZMLPEIWWJJO-RXFUPMDVSA-O CNC([C@H]([C@H]([C@H]1O)[NH3+])O[C@H]1N1C2=NC=NC(NCC(C=C(C=C3)Cl)=C3OCC3=CC=CC=C3)=C2N=C1)=O.[N-]=[N+]=[N-] Chemical compound CNC([C@H]([C@H]([C@H]1O)[NH3+])O[C@H]1N1C2=NC=NC(NCC(C=C(C=C3)Cl)=C3OCC3=CC=CC=C3)=C2N=C1)=O.[N-]=[N+]=[N-] SHJZMLPEIWWJJO-RXFUPMDVSA-O 0.000 description 1
101100112111 Caenorhabditis elegans cand-1 gene Proteins 0.000 description 1
101100079984 Caenorhabditis elegans nhr-9 gene Proteins 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
206010007556 Cardiac failure acute Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
229910052684 Cerium Inorganic materials 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
108020005199 Dehydrogenases Proteins 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
101100001672 Emericella variicolor andG gene Proteins 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229940121931 Gluconeogenesis inhibitor Drugs 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018985 Haemorrhage intracranial Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
UHLRAJBHKALTEF-KKMBPYAXSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)NC)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)NC)C(=O)O UHLRAJBHKALTEF-KKMBPYAXSA-N 0.000 description 1
OLHTWWGMYIAKFE-JBYGMCGMSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C)C(=O)O OLHTWWGMYIAKFE-JBYGMCGMSA-N 0.000 description 1
PHPNFLNRXVTUFR-XIXAVDCQSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CC1)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CC1)C(=O)O PHPNFLNRXVTUFR-XIXAVDCQSA-N 0.000 description 1
RKKFTZKDDGSGHJ-WCJVPVSSSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CCCC1)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)C1CCCC1)C(=O)O RKKFTZKDDGSGHJ-WCJVPVSSSA-N 0.000 description 1
OIIQUNGCLYJNCO-JBYGMCGMSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=C(OC(=C1)C)C)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=C(OC(=C1)C)C)C(=O)O OIIQUNGCLYJNCO-JBYGMCGMSA-N 0.000 description 1
SDCSNAFWFHUKBB-PTSPBZQHSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=CC(=CC=C1)OCCN1CCOCC1)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=CC(=CC=C1)OCCN1CCOCC1)C(=O)O SDCSNAFWFHUKBB-PTSPBZQHSA-N 0.000 description 1
DZUQUCNXGWNUQR-YNFBMLRVSA-N N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCCN1CCOCC1)C(=O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCCN1CCOCC1)C(=O)O DZUQUCNXGWNUQR-YNFBMLRVSA-N 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
238000012565 NMR experiment Methods 0.000 description 1
SVZOXQKFCRYGSM-RWRPPVFZSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CC(NC(C1)C)C)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CC(NC(C1)C)C)C(=O)O SVZOXQKFCRYGSM-RWRPPVFZSA-N 0.000 description 1
HJAVFTDIPIXMER-JBYGMCGMSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)N)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)N)C(=O)O HJAVFTDIPIXMER-JBYGMCGMSA-N 0.000 description 1
WFUPTZAIOMAOSE-KKMBPYAXSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)NC)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCC(CC1)NC)C(=O)O WFUPTZAIOMAOSE-KKMBPYAXSA-N 0.000 description 1
FFTMZRSHOZYSIL-KKMBPYAXSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)CC)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(=O)N1CCN(CC1)CC)C(=O)O FFTMZRSHOZYSIL-KKMBPYAXSA-N 0.000 description 1
JSMIURYNXWEHJD-YNFBMLRVSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(N1CCNCC1)=O)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC(N1CCNCC1)=O)C(=O)O JSMIURYNXWEHJD-YNFBMLRVSA-N 0.000 description 1
AFYZOHYKYPXLMZ-PTSPBZQHSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=CC(=CC=C1)OCCN1CCOCC1)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC1=CC(=CC=C1)OCCN1CCOCC1)C(=O)O AFYZOHYKYPXLMZ-PTSPBZQHSA-N 0.000 description 1
ZSXLTHGBZMVJIP-YNFBMLRVSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC=1C(=NOC1C)C)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC=1C(=NOC1C)C)C(=O)O ZSXLTHGBZMVJIP-YNFBMLRVSA-N 0.000 description 1
IHPSHYOVHPZIAN-KKMBPYAXSA-N N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC=1OC(=CC1)CN(C)C)C(=O)O Chemical compound N[C@@H]1[C@H](O[C@H]([C@@H]1O)N1C2=NC=NC(=C2N=C1)NCC1=C(C=CC(=C1)Cl)OCC=1OC(=CC1)CN(C)C)C(=O)O IHPSHYOVHPZIAN-KKMBPYAXSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000009569 Phosphoglucomutase Human genes 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
108010065084 Phosphorylase a Proteins 0.000 description 1
UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
229940127315 Potassium Channel Openers Drugs 0.000 description 1
208000023146 Pre-existing disease Diseases 0.000 description 1
229940123934 Reductase inhibitor Drugs 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 description 1
108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
MBVRBIMOXLDWAR-UHFFFAOYSA-N [2-(1,3-benzothiazol-2-ylmethoxy)-5-chlorophenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1=NC2=CC=CC=C2S1 MBVRBIMOXLDWAR-UHFFFAOYSA-N 0.000 description 1
IUTQWJHTIGRMQJ-UHFFFAOYSA-N [2-(1-benzofuran-2-ylmethoxy)-5-chlorophenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1=CC2=CC=CC=C2O1 IUTQWJHTIGRMQJ-UHFFFAOYSA-N 0.000 description 1
CSXQVNVXYKEPEV-UHFFFAOYSA-N [2-phenylmethoxy-5-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC(C(F)(F)F)=CC=C1OCC1=CC=CC=C1 CSXQVNVXYKEPEV-UHFFFAOYSA-N 0.000 description 1
KUIHILBCDBZAKB-UHFFFAOYSA-N [2-phenylmethoxy-5-(trifluoromethyl)phenyl]methanol Chemical compound OCC1=CC(C(F)(F)F)=CC=C1OCC1=CC=CC=C1 KUIHILBCDBZAKB-UHFFFAOYSA-N 0.000 description 1
HPRQKYQJUZTLIC-UHFFFAOYSA-N [5-chloro-2-(1,2-thiazol-5-ylmethoxy)phenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1=CC=NS1 HPRQKYQJUZTLIC-UHFFFAOYSA-N 0.000 description 1
LQXYHOKSYQKCON-UHFFFAOYSA-N [5-chloro-2-(1,3-thiazol-2-ylmethoxy)phenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1=NC=CS1 LQXYHOKSYQKCON-UHFFFAOYSA-N 0.000 description 1
UAHFJYGTMIOYIE-UHFFFAOYSA-N [5-chloro-2-(2-morpholin-4-ylethoxy)phenyl]methanamine;hydrochloride Chemical compound Cl.NCC1=CC(Cl)=CC=C1OCCN1CCOCC1 UAHFJYGTMIOYIE-UHFFFAOYSA-N 0.000 description 1
IUDXACSUFRVOBX-UHFFFAOYSA-N [5-chloro-2-(4,5-dihydro-1h-imidazol-2-ylmethoxy)phenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1=NCCN1 IUDXACSUFRVOBX-UHFFFAOYSA-N 0.000 description 1
UKSKBMOYRRHFKR-UHFFFAOYSA-N [5-chloro-2-(cyclopentylmethoxy)phenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1CCCC1 UKSKBMOYRRHFKR-UHFFFAOYSA-N 0.000 description 1
XJOMUVZWEGJZKG-UHFFFAOYSA-N [5-chloro-2-(furan-3-ylmethoxy)phenyl]methanamine;hydrochloride Chemical compound Cl.NCC1=CC(Cl)=CC=C1OCC1=COC=C1 XJOMUVZWEGJZKG-UHFFFAOYSA-N 0.000 description 1
ZLJOXJIYSZMFOB-UHFFFAOYSA-N [5-chloro-2-(oxolan-3-ylmethoxy)phenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1COCC1 ZLJOXJIYSZMFOB-UHFFFAOYSA-N 0.000 description 1
XPCHJLVHBHPLJY-UHFFFAOYSA-N [5-chloro-2-(oxolan-3-ylmethoxy)phenyl]methanamine;hydrochloride Chemical compound Cl.NCC1=CC(Cl)=CC=C1OCC1COCC1 XPCHJLVHBHPLJY-UHFFFAOYSA-N 0.000 description 1
GECTZAHNRZKVTO-UHFFFAOYSA-N [5-chloro-2-(pyridin-3-ylmethoxy)phenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1=CC=CN=C1 GECTZAHNRZKVTO-UHFFFAOYSA-N 0.000 description 1
GGGPOOFDHZCYHX-UHFFFAOYSA-N [5-chloro-2-(quinolin-2-ylmethoxy)phenyl]methanamine Chemical compound NCC1=CC(Cl)=CC=C1OCC1=CC=C(C=CC=C2)C2=N1 GGGPOOFDHZCYHX-UHFFFAOYSA-N 0.000 description 1
WOBIGNCERAZJMW-UHFFFAOYSA-N [5-chloro-2-[(2,5-dimethoxyphenyl)methoxy]phenyl]methanamine;hydrochloride Chemical compound Cl.COC1=CC=C(OC)C(COC=2C(=CC(Cl)=CC=2)CN)=C1 WOBIGNCERAZJMW-UHFFFAOYSA-N 0.000 description 1
XRLKUGDKEYBTCQ-UHFFFAOYSA-N [5-chloro-2-[(2,5-dimethylfuran-3-yl)methoxy]phenyl]methanamine Chemical compound O1C(C)=CC(COC=2C(=CC(Cl)=CC=2)CN)=C1C XRLKUGDKEYBTCQ-UHFFFAOYSA-N 0.000 description 1
XRXBBSFJOCGVGJ-UHFFFAOYSA-N [5-chloro-2-[(2-chlorophenyl)methoxy]phenyl]methanamine;hydrochloride Chemical compound Cl.NCC1=CC(Cl)=CC=C1OCC1=CC=CC=C1Cl XRXBBSFJOCGVGJ-UHFFFAOYSA-N 0.000 description 1
KYBJLIRIOKQXHS-UHFFFAOYSA-N [5-chloro-2-[(2-methylphenyl)methoxy]phenyl]methanamine;hydrochloride Chemical compound Cl.CC1=CC=CC=C1COC1=CC=C(Cl)C=C1CN KYBJLIRIOKQXHS-UHFFFAOYSA-N 0.000 description 1
QWXQJANCCORPPV-UHFFFAOYSA-N [5-chloro-2-[(3-chlorophenyl)methoxy]phenyl]methanamine;hydrochloride Chemical compound Cl.NCC1=CC(Cl)=CC=C1OCC1=CC=CC(Cl)=C1 QWXQJANCCORPPV-UHFFFAOYSA-N 0.000 description 1
ROZZABUAXUQMTP-UHFFFAOYSA-N [5-chloro-2-[(3-methoxyphenyl)methoxy]phenyl]methanamine;hydrochloride Chemical compound Cl.COC1=CC=CC(COC=2C(=CC(Cl)=CC=2)CN)=C1 ROZZABUAXUQMTP-UHFFFAOYSA-N 0.000 description 1
DYKWESRRSIDBLT-UHFFFAOYSA-N [5-chloro-2-[(3-methylphenyl)methoxy]phenyl]methanamine;hydrochloride Chemical compound Cl.CC1=CC=CC(COC=2C(=CC(Cl)=CC=2)CN)=C1 DYKWESRRSIDBLT-UHFFFAOYSA-N 0.000 description 1
ZZGGOPYJROJAFX-UHFFFAOYSA-N [5-chloro-2-[(4-methoxyphenyl)methoxy]phenyl]methanamine Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(Cl)C=C1CN ZZGGOPYJROJAFX-UHFFFAOYSA-N 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
OSLGUGPHJWPLED-UHFFFAOYSA-N [O].[O-][N+]#N Chemical compound [O].[O-][N+]#N OSLGUGPHJWPLED-UHFFFAOYSA-N 0.000 description 1
RGTGNSLGFMHBDM-UHFFFAOYSA-J [Zn++].[Cd++].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O Chemical compound [Zn++].[Cd++].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RGTGNSLGFMHBDM-UHFFFAOYSA-J 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004849 alkoxymethyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
239000011609 ammonium molybdate Substances 0.000 description 1
235000018660 ammonium molybdate Nutrition 0.000 description 1
APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
229940010552 ammonium molybdate Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
CQKDHWJCNNENAO-UHFFFAOYSA-N benzyl 5-methyl-2-phenylmethoxybenzoate Chemical compound C=1C=CC=CC=1COC(=O)C1=CC(C)=CC=C1OCC1=CC=CC=C1 CQKDHWJCNNENAO-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003939 benzylamines Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
150000005347 biaryls Chemical class 0.000 description 1
230000004321 blink reflex Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229960001035 bopindolol Drugs 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
QCUOBSQYDGUHHT-UHFFFAOYSA-L cadmium sulfate Chemical compound [Cd+2].[O-]S([O-])(=O)=O QCUOBSQYDGUHHT-UHFFFAOYSA-L 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical compound CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
VMKJWLXVLHBJNK-UHFFFAOYSA-N cyanuric fluoride Chemical compound FC1=NC(F)=NC(F)=N1 VMKJWLXVLHBJNK-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
239000003954 decarboxylase inhibitor Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
229940120124 dichloroacetate Drugs 0.000 description 1
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
229950010170 epalrestat Drugs 0.000 description 1
CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000012632 fluorescent imaging Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
102000046278 human ADORA3 Human genes 0.000 description 1
JKXCZYCVHPKTPK-UHFFFAOYSA-N hydrate;trihydrochloride Chemical compound O.Cl.Cl.Cl JKXCZYCVHPKTPK-UHFFFAOYSA-N 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
229960004569 indapamide Drugs 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
125000006480 iodobenzyl group Chemical group 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
229960000201 isosorbide dinitrate Drugs 0.000 description 1
229960003827 isosorbide mononitrate Drugs 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000011968 lewis acid catalyst Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
229940107698 malachite green Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000005399 mechanical ventilation Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003134 mepindolol Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
IXHZGHPQQTXOKV-UHFFFAOYSA-N methyl oxolane-2-carboxylate Chemical compound COC(=O)C1CCCO1 IXHZGHPQQTXOKV-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
229960003746 metildigoxin Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical compound N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
230000010016 myocardial function Effects 0.000 description 1
DPPAQYSYEWTCPT-UHFFFAOYSA-N n-(diaminomethylidene)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-ethylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(OCCO2)C2=C1 DPPAQYSYEWTCPT-UHFFFAOYSA-N 0.000 description 1
CMULWUTYYYBQQN-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-(1h-indazol-6-yl)pyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(C=NN2)C2=C1 CMULWUTYYYBQQN-UHFFFAOYSA-N 0.000 description 1
WZNARTSEKZYYQH-UHFFFAOYSA-N n-(diaminomethylidene)-5-ethyl-1-quinolin-6-ylpyrazole-4-carboxamide Chemical compound CCC1=C(C(=O)NC(N)=N)C=NN1C1=CC=C(N=CC=C2)C2=C1 WZNARTSEKZYYQH-UHFFFAOYSA-N 0.000 description 1
AVPCCSOPUUKTNW-UHFFFAOYSA-N n-[1-methyl-2-[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]benzimidazol-5-yl]-2-(4-nitrophenoxy)acetamide Chemical compound N=1C2=CC(NC(=O)COC=3C=CC(=CC=3)[N+]([O-])=O)=CC=C2N(C)C=1CCN(CC1)CCN1C1=CC=CC=N1 AVPCCSOPUUKTNW-UHFFFAOYSA-N 0.000 description 1
NKTOWTMAYSMNJR-UHFFFAOYSA-N n-[[5-chloro-2-[(3-methyl-1,2-oxazol-5-yl)methoxy]phenyl]methyl]-7h-purin-6-amine Chemical compound O1N=C(C)C=C1COC1=CC=C(Cl)C=C1CNC1=C2N=CN=C2N=CN1 NKTOWTMAYSMNJR-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
229960004255 nadolol Drugs 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229960005425 nitrendipine Drugs 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000003585 oxepinyl group Chemical group 0.000 description 1
238000012858 packaging process Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
108091000115 phosphomannomutase Proteins 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
229960001085 piretanide Drugs 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229950010884 ponalrestat Drugs 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
AMMGCGVWJMRTQI-UHFFFAOYSA-N prop-1-en-2-yl carbonochloridate Chemical compound CC(=C)OC(Cl)=O AMMGCGVWJMRTQI-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
239000008213 purified water Substances 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
208000022064 reactive hyperemia Diseases 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
238000002310 reflectometry Methods 0.000 description 1
229940107685 reopro Drugs 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000002002 slurry Substances 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
LXANPKRCLVQAOG-NSHDSACASA-N sorbinil Chemical compound C12=CC(F)=CC=C2OCC[C@@]21NC(=O)NC2=O LXANPKRCLVQAOG-NSHDSACASA-N 0.000 description 1
229950004311 sorbinil Drugs 0.000 description 1
229960002370 sotalol Drugs 0.000 description 1
ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
XMZFHDMOAXSFDS-UHFFFAOYSA-N tert-butyl n-[[5-chloro-2-(cyanomethoxy)phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC(Cl)=CC=C1OCC#N XMZFHDMOAXSFDS-UHFFFAOYSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 1
229960003069 tolrestat Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
229960000537 xipamide Drugs 0.000 description 1
SXONDGSPUVNZLO-UHFFFAOYSA-N zenarestat Chemical compound O=C1N(CC(=O)O)C2=CC(Cl)=CC=C2C(=O)N1CC1=CC=C(Br)C=C1F SXONDGSPUVNZLO-UHFFFAOYSA-N 0.000 description 1
229950006343 zenarestat Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Saccharide Compounds (AREA)

OA1200200072A 1999-09-30 2000-09-22 Compounds for the treatment of ischemia. OA12021A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15682899P	1999-09-30	1999-09-30

Publications (1)

Publication Number	Publication Date
OA12021A true OA12021A (en)	2006-04-19

Family

ID=22561263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200072A OA12021A (en)	1999-09-30	2000-09-22	Compounds for the treatment of ischemia.

Country Status (41)

Country	Link
EP (1)	EP1216257B1 (fr)
JP (1)	JP2003510331A (fr)
KR (1)	KR100481605B1 (fr)
CN (1)	CN1374967A (fr)
AP (1)	AP2002002458A0 (fr)
AR (1)	AR029887A1 (fr)
AT (1)	ATE312117T1 (fr)
AU (1)	AU778185B2 (fr)
BG (1)	BG106636A (fr)
BR (1)	BR0014384A (fr)
CA (1)	CA2386079A1 (fr)
CO (1)	CO5180581A1 (fr)
CR (1)	CR6592A (fr)
CZ (1)	CZ20021020A3 (fr)
DE (1)	DE60024649D1 (fr)
EA (1)	EA005422B1 (fr)
EC (1)	ECSP003682A (fr)
EE (1)	EE200200172A (fr)
GE (1)	GEP20043241B (fr)
GT (1)	GT200000161A (fr)
HK (1)	HK1049011A1 (fr)
HR (1)	HRP20020253A2 (fr)
HU (1)	HUP0202807A3 (fr)
IL (1)	IL148222A0 (fr)
IS (1)	IS6286A (fr)
MA (1)	MA26822A1 (fr)
MX (1)	MXPA02003308A (fr)
MY (1)	MY133996A (fr)
NO (1)	NO20021474L (fr)
NZ (1)	NZ517177A (fr)
OA (1)	OA12021A (fr)
PA (1)	PA8503301A1 (fr)
PE (1)	PE20010696A1 (fr)
PL (1)	PL357371A1 (fr)
SK (1)	SK4182002A3 (fr)
TN (1)	TNSN00191A1 (fr)
TR (1)	TR200200843T2 (fr)
UA (1)	UA73525C2 (fr)
WO (1)	WO2001023399A1 (fr)
YU (1)	YU23102A (fr)
ZA (1)	ZA200202461B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6803457B1 (en)	1999-09-30	2004-10-12	Pfizer, Inc.	Compounds for the treatment of ischemia
EP1241176A1 (fr) *	2001-03-16	2002-09-18	Pfizer Products Inc.	Dérivés de purine pour le traitement de l'ischémie
KR20050042225A (ko) *	2001-11-02	2005-05-06	아벤티스 파마슈티칼스 인크.	아데노신 ａ1/ａ2 효능제 및 나트륨 수소 교환 억제제를포함하는 약제학적 조성물
US7414036B2 (en)	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
CA2482928A1 (fr)	2002-04-18	2003-10-30	Cv Therapeutics, Inc.	Procede de traitement des arythmies consistant a administrer un agoniste d'adenosine a1 avec un betabloquant, un inhibiteur calcique ou un glucoside cardiotonique
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
RU2006120084A (ru) *	2003-11-10	2008-01-10	Шеринг Акциенгезельшафт (De)	Бензилэфирамины, полезные как антагонисты ccr-5
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US8293791B2 (en)	2004-03-24	2012-10-23	Fasgen, Llc	Method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase
EA011097B1 (ru)	2004-05-07	2008-12-30	Янссен Фармацевтика Н.В.	Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
EP1778239B1 (fr) *	2004-07-28	2013-08-21	Can-Fite Biopharma Ltd.	Agonistes du recepteur de l'adenosine a3 pour le traitement de troubles de l'oeil sec tels que le syndrome de sjogren
WO2006015830A1 (fr) *	2004-08-09	2006-02-16	Universite Catholique De Louvain	Utilisation d’agonistes et d’antagonistes de bêta-adrénocepteurs pour traiter les maladies artérielles
KR101197672B1 (ko)	2004-08-30	2012-11-07	얀센 파마슈티카 엔.브이.	11-베타 하이드록시스테로이드 데하이드로게나제저해제로서 트리사이클릭 락탐 유도체
AU2005279208B2 (en) *	2004-08-30	2011-02-24	Janssen Pharmaceutica N.V.	N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de)	2004-08-30	2009-11-26	Janssen Pharmaceutica Nv	Oxysteroid-dehydrogenase-inhibitoren
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
JP5006330B2 (ja)	2005-10-21	2012-08-22	ノバルティスアーゲー	Ｉｌ１３に対するヒト抗体および治療的使用
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
KR20090073121A (ko)	2006-09-29	2009-07-02	노파르티스 아게	Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
US20100041662A1 (en)	2006-10-30	2010-02-18	Sandrine Ferrand	Heterocyclic compounds as antiinflammatory agents
WO2009087224A1 (fr)	2008-01-11	2009-07-16	Novartis Ag	Pyrimidines utilisés en tant qu'inhibiteurs de kinase
TW201031406A (en)	2009-01-29	2010-09-01	Novartis Ag	Substituted benzimidazoles for the treatment of astrocytomas
US9199102B2 (en)	2009-07-21	2015-12-01	Oradin Pharmaceutical Ltd.	A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
CN102573846B (zh)	2009-08-17	2015-10-07	因特利凯公司	杂环化合物及其用途
MX2012002179A (es)	2009-08-20	2012-03-16	Novartis Ag	Compuestos heterociclicos de oxima.
WO2012034095A1 (fr)	2010-09-09	2012-03-15	Irm Llc	Composés et compositions comme inhibiteurs de trk
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
US20130324526A1 (en)	2011-02-10	2013-12-05	Novartis Ag	[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en)	2011-02-23	2015-09-08	Intellikine, LLC.	Heterocyclic compounds and uses thereof
JP5959541B2 (ja)	2011-02-25	2016-08-02	ノバルティスアーゲー	Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
EP2755976B1 (fr)	2011-09-15	2018-07-18	Novartis AG	3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
CA2856803A1 (fr)	2011-11-23	2013-05-30	Intellikine, Llc	Regimes de traitement ameliores utilisant des inhibiteurs de mtor
ES2894830T3 (es)	2012-04-03	2022-02-16	Novartis Ag	Productos combinados con inhibidores de tirosina·cinasa y su uso
BR112014027983B1 (pt)	2012-05-08	2022-05-24	Aeromics, Inc	Uso de inibidores de aquaporina seletivos
RU2559776C2 (ru) *	2012-08-20	2015-08-10	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
CN105246482A (zh)	2013-03-15	2016-01-13	因特利凯有限责任公司	激酶抑制剂的组合及其用途
WO2015069961A1 (fr)	2013-11-06	2015-05-14	Aeromics, Llc	Nouveaux sels de promédicament
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
RU2611339C2 (ru) *	2014-02-17	2017-02-21	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (fr)	2014-07-25	2016-01-28	Novartis Ag	Polythérapie
KR20170036037A (ko)	2014-07-31	2017-03-31	노파르티스 아게	조합 요법
RU2582961C1 (ru) *	2015-03-04	2016-04-27	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
CN113194752A (zh)	2018-06-01	2021-07-30	康奈尔大学	Pi3k相关疾病或病症的组合疗法
RU2712150C1 (ru) *	2019-08-22	2020-01-24	Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех"	ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK62692D0 (fr) *	1992-05-14	1992-05-14	Novo Nordisk As
TW336938B (en) *	1992-05-21	1998-07-21	Pfizer	Calcium channel blocking polypeptides from filistata hibernalis
US5773423A (en) *	1993-07-13	1998-06-30	The United States Of America As Represented By The Department Of Health And Human Services	A3 adenosine receptor agonists

2000
- 2000-09-05 CO CO00066880A patent/CO5180581A1/es not_active Application Discontinuation
- 2000-09-22 EA EA200200316A patent/EA005422B1/ru not_active IP Right Cessation
- 2000-09-22 EP EP00958949A patent/EP1216257B1/fr not_active Expired - Lifetime
- 2000-09-22 BR BR0014384-7A patent/BR0014384A/pt not_active IP Right Cessation
- 2000-09-22 MX MXPA02003308A patent/MXPA02003308A/es unknown
- 2000-09-22 AT AT00958949T patent/ATE312117T1/de not_active IP Right Cessation
- 2000-09-22 EE EEP200200172A patent/EE200200172A/xx unknown
- 2000-09-22 UA UA2002032515A patent/UA73525C2/uk unknown
- 2000-09-22 AU AU70352/00A patent/AU778185B2/en not_active Ceased
- 2000-09-22 CZ CZ20021020A patent/CZ20021020A3/cs unknown
- 2000-09-22 SK SK418-2002A patent/SK4182002A3/sk unknown
- 2000-09-22 HK HK03101216.3A patent/HK1049011A1/zh unknown
- 2000-09-22 CA CA002386079A patent/CA2386079A1/fr not_active Abandoned
- 2000-09-22 TR TR2002/00843T patent/TR200200843T2/xx unknown
- 2000-09-22 GE GEAP20006392A patent/GEP20043241B/en unknown
- 2000-09-22 NZ NZ517177A patent/NZ517177A/en unknown
- 2000-09-22 PL PL00357371A patent/PL357371A1/xx not_active Application Discontinuation
- 2000-09-22 JP JP2001526549A patent/JP2003510331A/ja active Pending
- 2000-09-22 OA OA1200200072A patent/OA12021A/en unknown
- 2000-09-22 DE DE60024649T patent/DE60024649D1/de not_active Expired - Lifetime
- 2000-09-22 WO PCT/IB2000/001353 patent/WO2001023399A1/fr not_active Ceased
- 2000-09-22 YU YU23102A patent/YU23102A/sh unknown
- 2000-09-22 AP APAP/P/2002/002458A patent/AP2002002458A0/en unknown
- 2000-09-22 HR HR20020253A patent/HRP20020253A2/xx not_active Application Discontinuation
- 2000-09-22 KR KR10-2002-7004177A patent/KR100481605B1/ko not_active Expired - Fee Related
- 2000-09-22 CN CN00813154A patent/CN1374967A/zh active Pending
- 2000-09-22 HU HU0202807A patent/HUP0202807A3/hu unknown
- 2000-09-25 PA PA20008503301A patent/PA8503301A1/es unknown
- 2000-09-27 PE PE2000001021A patent/PE20010696A1/es not_active Application Discontinuation
- 2000-09-28 AR ARP000105125A patent/AR029887A1/es unknown
- 2000-09-28 GT GT200000161A patent/GT200000161A/es unknown
- 2000-09-28 MY MYPI20004553 patent/MY133996A/en unknown
- 2000-09-28 EC EC2000003682A patent/ECSP003682A/es unknown
- 2000-09-29 IL IL14822200A patent/IL148222A0/xx unknown
- 2000-09-29 TN TNTNSN00191A patent/TNSN00191A1/fr unknown
2002
- 2002-02-18 CR CR6592A patent/CR6592A/es not_active Application Discontinuation
- 2002-02-26 IS IS6286A patent/IS6286A/is unknown
- 2002-03-15 MA MA26557A patent/MA26822A1/fr unknown
- 2002-03-25 NO NO20021474A patent/NO20021474L/no unknown
- 2002-03-27 ZA ZA200202461A patent/ZA200202461B/xx unknown
- 2002-04-23 BG BG106636A patent/BG106636A/bg unknown

Also Published As

Publication number	Publication date
BR0014384A (pt)	2002-07-02
HUP0202807A3 (en)	2005-02-28
PE20010696A1 (es)	2001-07-05
CN1374967A (zh)	2002-10-16
AU778185B2 (en)	2004-11-18
AP2002002458A0 (en)	2002-06-30
NZ517177A (en)	2003-10-31
TNSN00191A1 (fr)	2005-11-10
SK4182002A3 (en)	2003-04-01
CO5180581A1 (es)	2002-07-30
EP1216257B1 (fr)	2005-12-07
KR100481605B1 (ko)	2005-04-08
MY133996A (en)	2007-11-30
EA005422B1 (ru)	2005-02-24
HK1049011A1 (zh)	2003-04-25
ECSP003682A (es)	2002-04-23
BG106636A (bg)	2003-01-31
MXPA02003308A (es)	2002-10-04
CR6592A (es)	2004-02-23
HUP0202807A2 (hu)	2002-12-28
TR200200843T2 (tr)	2002-07-22
MA26822A1 (fr)	2004-12-20
PA8503301A1 (es)	2003-06-30
YU23102A (sh)	2006-01-16
AU7035200A (en)	2001-04-30
EA200200316A1 (ru)	2002-08-29
WO2001023399A1 (fr)	2001-04-05
CZ20021020A3 (cs)	2003-04-16
KR20020034206A (ko)	2002-05-08
NO20021474L (no)	2002-05-22
IL148222A0 (en)	2002-09-12
JP2003510331A (ja)	2003-03-18
GEP20043241B (en)	2004-05-25
AR029887A1 (es)	2003-07-23
CA2386079A1 (fr)	2001-04-05
ATE312117T1 (de)	2005-12-15
UA73525C2 (en)	2005-08-15
NO20021474D0 (no)	2002-03-25
PL357371A1 (en)	2004-07-26
EP1216257A1 (fr)	2002-06-26
IS6286A (is)	2002-02-26
EE200200172A (et)	2003-06-16
ZA200202461B (en)	2003-05-28
HRP20020253A2 (en)	2004-04-30
GT200000161A (es)	2002-03-22
DE60024649D1 (de)	2006-01-12

Publication	Publication Date	Title
OA12021A (en)	2006-04-19	Compounds for the treatment of ischemia.
US6803457B1 (en)	2004-10-12	Compounds for the treatment of ischemia
US20030055021A1 (en)	2003-03-20	Compounds for the treatment of ischemia
AU739403B2 (en)	2001-10-11	N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia
ES2211806T3 (es)	2004-07-16	Derivados beta-carbolina utiles como inhibidores de la fosfodiesterasa.
ES2379308T3 (es)	2012-04-24	Pirrolo[2,3-B]- y pirazolo[3,4-B]piridinas sustituidas como ligandos del receptor de adenosina
US9040516B2 (en)	2015-05-26	Uracil derivative and use thereof for medical purposes
WO2005012323A2 (fr)	2005-02-10	Composes utiles comme agonistes des recepteurs de l'adenosine a3
CN120752227A (zh)	2025-10-03	α，β-不饱和酰胺类化合物及其应用
HK1197675A (en)	2015-02-06	Uracil derivative and use thereof for medical purposes